Kontynuacja badania u pacjentów z nowotworami hematologicznymi wcześniej leczonych tafasitamabem.

Kryteria wyłączenia kto nie może wziąć udziału (6)

1. Patient who is legally institutionalized, or under judicial protection.
2. Has met one or more criteria for permanent tafasitamab treatment discontinuation as stipulated in the parent protocol.
3. Able to access tafasitamab outside a clinical study.
4. Patient with an uncontrolled intercurrent illness or any concurrent condition that, in the Investigator’s opinion, would jeopardize the safety of the patient or compliance with the protocol.
5. A female patient who is pregnant confirmed by a pregnancy test prior to enrollment, breastfeeding, or a woman of childbearing potential (WOCBP) (as defined in Appendix 5: Contraceptive Guidance and Collection of Pregnancy Information) who does not agree to follow the contraceptive guidance in Appendix 5: Contraceptive Guidance and Collection of Pregnancy Information during the treatment period and for at least 3 months after the last dose of study treatment, and does not refrain from donating oocytes during this period.
6. A male patient who does not agree to use contraception as detailed in Appendix 5: Contraceptive Guidance and Collection of Pregnancy Information during the treatment period and for at least 3 months after the last dose of study treatment (if they have a heterosexual partner who is a woman of childbearing potential) and who does not refrain from donating sperm during this period.